Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Know Your Unknown Unknowns

David S. Pisetsky, MD, PhD  |  Issue: October 2007  |  October 1, 2007

David S. Pisetsky, MD, PhD

During a press conference in 2002, then Secretary of Defense Donald Rumsfeld provided a categorization of information. To Rumsfeld, information could be divided into three types: known knowns, which are things that we know we know; known unknowns, which are things that we know we don’t know; and unknown unknowns, which are things that we don’t know we don’t know.

This categorization has been much discussed (as well as criticized, touted, and mocked, depending upon your point of view). While history will ultimately judge the wisdom of Rumsfeld’s policies, I am convinced that, when it comes to medicine, there is truth in his thinking. Indeed, I believe that dealing with unknowns – both known and unknown – is at the heart of medical practice and successful patient care comes from learning to make decisions in the face of the uncertain, the imprecise, and the imponderable.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

To illustrate this point, I would like to describe a case. This case is a classic example of known and unknown unknowns, and I want your opinion on its management. As you will see, this case is tricky because the rheumatologist was an adviser and not the decider.

Complex Case with a Surprise Twist

The case involved a woman in her 70s who had the usual set of medical conditions that comes with age. Her major complaint was ill-defined chest pain that led to an extensive cardiovascular work-up, which showed that, while her coronary arteries had the slightest occlusions, her thoracic aorta had a worrisome dilation. The surgeons were consulted. They diagnosed an aneurysm of the ascending thoracic aorta and, with abundant cutting and sewing skill, they replaced the troubled aortic segment with a fine new graft.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The diseased aorta – dunked immediately in a jar of formalin – made its way to the pathology department, where the findings were as dramatic as they were unexpected. Under the microscope, in the red and blue hues that are the hallmark colors of hematoxylin and eosin, the aorta was filled with inflammatory cells. Among their number, these cells included some hefty-looking giant cells filled with more than their share of nuclei. The diagnosis was clear: giant cell arteritis (GCA) of the aorta.

With the pathological diagnosis in hand, the surgeons consulted the rheumatology service for our recommendation. Our fellow saw the patient and, during a very thorough exam and methodical history, elicited none of the telltale symptoms of GCA: no throbbing headache, no scorching scalp pain, no curtains of darkness falling across the eyes. Certainly, the patient had her share of misery, but none that could point to vasculitis. Nevertheless, our service, worried that vasculitis could darken her vision forever or menace an artery to the brain, recommended an immediate course of steroids. We wanted the real deal: 1 mg/kg jet-sprayed into the IV that was still in place post-op.

Page: 1 2 3 | Single Page
Share: 

Filed under:OpinionRheuminationsSpeak Out RheumVasculitis Tagged with:Cardiovascular diseasecase reportDiagnostic CriteriaGiant Cell ArteritisGlucocorticoidsPathogenesisSteroidsTreatment

Related Articles

    Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

    March 1, 2013

    Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

    Updates on Giant Cell Arteritis

    March 19, 2018

    SAN DIEGO—Recent research tells us more about giant cell arteritis (GCA) to help rheumatologists more accurately diagnose and effectively treat patients with this type of vasculitis. On Nov. 6 at the ACR/ARHP Annual Meeting, three experts explored the latest findings on GCA pathogenesis, diagnostic approaches, imaging modalities and growing treatment options. GCA: What’s Really Happening?…

    Giant Cell Arteritis Challenging to Diagnose, Manage

    March 1, 2015

    Common form of primary vasculitis difficult to identify, treat, but latest research suggests potential new therapeutic targets

    Case Report: Giant Cell Arteritis-Related Stroke

    September 10, 2023

    Thromboembolic events are major contributors to the morbidity and mortality of patients with giant cell arteritis (GCA), but little is known about how GCA may increase the risk of ischemic strokes. GCA-related stroke is described as an ischemic cerebral infarct occurring within three to four weeks of GCA diagnosis and treatment. It occurs in 3–7%…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences